0000000000620372

AUTHOR

Francesco Bernardi

showing 9 related works from this author

Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors.

2009

Combined deficiency of the vitamin K-dependent clotting factors (VKCFD) is a rare bleeding disorder involving defective gamma-carboxylation of coagulation factors II , VII, IX and X as well as natural anticoagulants protein C and protein S. The disease is characterized by a cluster of different, often life threatening, bleeding symptoms occurring both spontaneously and in a surgical setting. In the present paper we describe two different treatment modalities to be used both in a programmed surgical procedure and in an emergency scenario. As this disease is a natural model that resembles oral anticoagulation, our experience discloses a possible rationale in the use of recombinant activated …

VitaminAdultmedicine.medical_specialtyVitamin KBiopsyFactor VII DeficiencyHereditary Combined Deficiency of Vitamin K-dependent Clotting FactorsBlood Loss SurgicalDiseaseFactor VIIaGastroenterologyMixed Function Oxygenaseschemistry.chemical_compoundBlood Coagulation Disorders InheritedInternal medicineVitamin K Epoxide ReductasesGastroscopymedicineHumansRare Inherited Bleeding disorders Minor SurgeryOral anticoagulationClotting factorbusiness.industryHomozygoteWarfarinHematologyGeneral MedicineFactor VIIHemostasis SurgicalRecombinant ProteinsSurgeryCoagulationchemistryHemostasisTooth ExtractionFemaleBlood Coagulation TestsbusinessProtein Cmedicine.drugClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report

2012

Transplantation in patients with congenital bleeding disorders is a challenge requiring an integrated approach of various specialists. Renal transplantation, the most frequent type of solid organ transplantation, is rarely performed in individuals with congenital hemorrhagic disorders. We performed a renal transplantation in a 53-year-old man with end-stage renal disease and congenital coagulation factor VII deficiency, a rare bleeding disorder with a peculiar clinical picture requiring replacement therapy in surgical interventions. Perioperative bleeding was successfully prevented by administration of recombinant activated factor VII. Treatment schedule, administration rate, and long-term …

Malemedicine.medical_specialtyDiseaseHemorrhagic disorderchemistry.chemical_compoundHumansMedicinekidney transplatation congenital bleeding disorders factor VII deficiency recombinant factor VII major surgerykidney transplantation inherited coagulation disorderCoagulation factor VIIKidney transplantationTransplantationFactor VIIbusiness.industryPerioperativeMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationchemistryTreatment ScheduleFeasibility StudiesKidney Failure ChronicSurgerybusiness
researchProduct

Phytochemical Analysis and Cytotoxicity Towards Multidrug-Resistant Leukemia Cells of Essential Oils Derived from Lebanese Medicinal Plants

2012

Juniperus excelsa fruit essential oil as well as J. oxycedrus, Cedrus libani, and Pinus pinea wood essential oils have been obtained with yields between 2.2 ± 0.3 % to 3.4 ± 0.5 % and analyzed by gas chromatography. Sesquiterpenes mainly characterized C. libani and J. oxycedrus essential oils, while in P. pinea and J. excelsa, monoterpenes were the most abundant compounds. In J. oxycedrus, cis-calamenene (7.8 %), cuparene (3.8 %), and cis-thujopsenal (2.0 %) have been detected for the first time. The cytotoxic activity of these essential oils against drug-sensitive CCRF-CEM and multidrug-resistant P-glycoprotein-expressing CEM/ADR5000 leukemia cells has been investigated (IC₅₀ values: 29.46…

Cupressaceaegas chromatographyPharmaceutical ScienceAnalytical Chemistrylaw.inventionlawDrug DiscoveryTumor Cells CulturedLebanonMedicinal plantsLeukemiabiologyTraditional medicinePinaceaeWoodDrug Resistance MultiplePhytochemicalJuniperus excelsaPinaceaeMolecular MedicineSesquiterpenesJuniperus oxycedruscancer; essential oils; gas chromatography; multidrug resistance; Juniperus excelsa; Juniperus oxycedrus; Cupressaceae; Cedrus libani; Pinus pinea; PinaceaeNOmultidrug resistanceBotanyOils VolatileHumanscancerCedrusessential oilsEssential oilCedrus libaniPharmacologyPlants MedicinalOrganic ChemistryCupressaceaePinusbiology.organism_classificationCedrus libaniAntineoplastic Agents PhytogenicComplementary and alternative medicineDrug Resistance NeoplasmFruitJuniperusMonoterpenesPinus pineaJuniperus excelsaJuniperus oxycedrusPhytotherapyPlanta Medica
researchProduct

VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY

2008

Summary.  Background: Combined vitamin K-dependent clotting factor (VKCF) deficiency type 2 (VKCFD2) is a rare bleeding disorder caused by mutated vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) gene. Methods and results: An Italian patient with moderate to severe bleeding tendency was genotyped, and found to be homozygous for the unique VKORC1 mutation (Arg98Trp) so far detected in VKCFD2. The activity levels of VKCFs were differentially reduced, and inversely related to the previously estimated affinity of procoagulant factor propeptides for the γ-carboxylase. The normal (factor IX) or reduced antigen levels (other VKCFs) produced a gradient in specific activities. Vitamin K su…

Adultmedicine.medical_specialtycoagulation factor levelsVitamin KProtein SMixed Function OxygenasesTissue factorchemistry.chemical_compoundInternal medicineVitamin K Epoxide ReductasesmedicineVKCFD2HumansFactor IXClotting factorCoagulation factor levels; Thrombin generation; Vitamin K supplementation; VKCFD2; VKORC1 mutation;biologyFactor VIIChemistryFactor XHomozygotevitamin K supplementationHematologyBlood Coagulation DisordersEndocrinologyTreatment OutcomeCoagulationthrombin generationImmunologyMutationbiology.proteinFemaleBlood Coagulation TestsVKCFD2 VKORC1 mutation coagulation factor levels thrombin generation vitamin K supplementationProtein Cmedicine.drugHalf-LifeVKORC1 mutation
researchProduct

Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency.

2012

We report 2 asymptomatic homozygotes for the nonsense p.R462X mutation affecting the carboxy-terminus of coagulation factor VII (FVII, 466 aminoacids). FVII levels of 3-5% and 2.7 ± 0.4% were found in prothrombin time-based and activated factor X (FXa) generation assays with human thromboplastins. Noticeably, FVII antigen levels were barely detectable (0.7 ± 0.2%) which suggested a gain-of-function effect. This effect was more pronounced with bovine thromboplastin (4.8 ± 0.9%) and disappeared with rabbit thromboplastin (0.7 ± 0.2%). This suggests that the mutation influences tissue factor/FVII interactions. Whereas the recombinant rFVII-462X variant confirmed an increase in specific activit…

MaleProteasesHeterozygoteFactor VII DeficiencyEnzyme-Linked Immunosorbent AssayFVIIBiologymedicine.disease_causeThromboplastinTissue factorchemistry.chemical_compoundCarboxy-terminalhemic and lymphatic diseasesmedicineFACTOR VII DEFICIENCY MOLECULAR VARIANTSThromboplastinMissense mutationAnimalsHumanscardiovascular diseasesChildBlood CoagulationProthrombin timeMutationmedicine.diagnostic_testFactor VIIHomozygoteHematologyFactor VIIMiddle AgedMolecular biologyAsymptomatic; Carboxy-terminal; FVII; Mutation;AsymptomaticchemistryCoagulationCodon NonsenseMutationMutagenesis Site-DirectedProthrombin TimeCattleFemaleRabbitsOriginal Articles and Brief Reports
researchProduct

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

2022

Background Circulating dysfunctional factor IX (FIX) might modulate distribution of infused FIX in hemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, >300 patients) are associated with variable FIX activity and antigen (FIXag) levels. Objectives To investigate the (1) expression of a complete panel of missense mutations at FIX activation sites and (2) contribution of F9 genotypes on the FIX pharmacokinetics (PK). Methods We checked FIX activity and antigen and activity assays in plasma and after recombinant expression of FIX variants and performed an analysis of infused FIX PK parameters in patients (n = 30), mostly enrolled in the F9 Genotype and PK HB …

medicine.medical_specialtypharmacogenetics.Mutation MissenseSocio-culturaleAlpha (ethology)aemophilia Brecombinant proteinsHemophilia Blaw.inventionFactor IXAntigenlawInternal medicineGenotypemedicineMissense mutationHumansHaemophilia BpharmacokineticBeta (finance)Factor IXpharmacogeneticsChemistryHematologymedicine.diseaseEndocrinologyPhenotypefactor IX activation; hemophilia B; pharmacogenetics; pharmacokinetics; recombinant proteinsRecombinant DNAFemalefactor IX activationBlood Coagulation Testspharmacokineticsrecombinant proteinmedicine.drugJournal of thrombosis and haemostasis : JTH
researchProduct

Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence f…

2018

Perioperative bleeding is a major concern in patients with factor VII (FVII) deficiency. Evaluating data of 95 FVII-deficient patients undergoing 110 surgical procedures (61 major, 49 minor), we assessed the impact of type of surgery, bleeding phenotype and FVII coagulant activity (FVII:C) levels on perioperative replacement therapy (RT). Compared to those with higher FVII:C levels, patients with <3% FVII:C received a higher number of RT doses (8 vs. 2, P = 0·003) for a longer RT duration (3 days vs. 1 day, P = 0·001), with no difference in RT dose. Similarly, patients with a history of major bleeds received a higher number of RT doses (8·5 vs. 2-3, P = 0·013) for a longer RT duration (2…

AdultMalemedicine.medical_specialtyAdolescentClinical Decision-MakingSocio-culturaleHemorrhage030204 cardiovascular system & hematologyIndependent predictorGastroenterologyAsymptomaticsurgery03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineInternal medicinemedicineHumansIn patientRegistriesFactor VII deficiencybleeding disordersbleeding disorderSurgical ProceduresFactor VIIbusiness.industryDisease ManagementPerioperativeHematologySurgical proceduresFactor VIIMiddle AgedCombined Modality TherapyOperativefactor VII deficiencyTreatment Outcomechemistry030220 oncology & carcinogenesisSurgical Procedures Operativebleeding disorders; factor VII deficiency; surgery; Adolescent; Adult; Clinical Decision-Making; Combined Modality Therapy; Disease Management; Factor VII; Factor VII Deficiency; Female; Hemorrhage; Humans; Male; Middle Aged; Registries; Surgical Procedures Operative; Symptom Assessment; Treatment Outcome; Young Adult; HematologyFemalemedicine.symptomSymptom AssessmentbusinessMajor bleeding
researchProduct

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolong…

2014

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect -

HeredityPharmacokinetic inherited Factor VII deficiencyFactor VII DeficiencySocio-culturaleFactor VIIaPharmacologySeverity of Illness IndexPharmacokineticsPredictive Value of Testshemic and lymphatic diseasesHumansMedicineGenetic Predisposition to DiseaseFVII deficiencyRegistriescardiovascular diseasesBlood CoagulationVolume of distributionbiologyCoagulantsbusiness.industryVascular biologyrFVIIaHematologyFactor VIIRecombinant ProteinsPhenotypeTreatment OutcomerFVIIa; FVII deficiency; pharmacokineticsRecombinant factor VIIaPharmacodynamicsbiology.proteinBlood Coagulation TestsSteady state (chemistry)Drug Monitoringbusinesspharmacokinetics
researchProduct

Thrombosis in inherited factor VII deficiency

2003

Thrombosis in congenital factor (F) VII deficiency was investigated through extensive phenotypic and molecular-genetic studies. Patients with a history of thrombosis among 514 entries in the FVII Deficiency Study Group database were evaluated. Thrombotic events were arterial in one case, disseminated intravascular coagulation in another and venous in seven. Gene mutations were characterized in eight patients: three were homozygous, three compound heterozygous and two heterozygous. FXa and IIa generation assays were consistent with the genetic lesions. One patient was heterozygous for the FV Leiden and one for the FIIG20210A mutation. In seven patients, surgical interventions and/or replacem…

AdultMaleHeterozygotemedicine.medical_specialtyPathologyTime FactorsAdolescentFactor VII DeficiencyGene mutationCompound heterozygosityThrombophiliaGastroenterologyInternal medicinemedicineHumansThrombophiliaAgedVenous ThrombosisDisseminated intravascular coagulationbiologybusiness.industryHomozygoteFactor VFactor VThrombosisHematologyCongenital FVII deficiency; Replacement therapy; Surgery; Thrombophilia; Thrombosis;Disseminated Intravascular CoagulationMiddle Agedmedicine.diseaseThrombosisZygosityVenous thrombosisPhenotypeDatabases as TopicFactor XaMutationbiology.proteinFemaleProthrombinbusinessJournal of Thrombosis and Haemostasis
researchProduct